市场调查报告书
商品编码
1395618
细胞冷冻保存全球市场规模、占有率、产业趋势分析报告:2023-2030 年按组件、最终用途和地区分類的展望和预测Global Cell Cryopreservation Market Size, Share & Industry Trends Analysis Report By Component, By End-use, By Application (Stem Cells, Oocytes & Embryotic cells, Sperm Cells, Hepatocytes), By Regional Outlook and Forecast, 2023 - 2030 |
预计到 2030 年,细胞冷冻保存市场规模将达到 357 亿美元,预测期内市场成长率为 20.3%。
根据 KBV Cardinal 矩阵中发表的分析,Thermo Fisher Scientific Inc 和 Danaher Corporation 是市场先驱。 2023年8月,赛默飞世尔科技推出TSV系列实验室冰箱和冷冻库。推出的产品均提供温度控制技术,包括超低温冷冻柜和冷冻储存槽,确保温度均匀性和稳定性,降低样品劣化风险。 Sartorius AG、Lonza Group AG 和 Merck KGAA 等公司是该市场的主要创新者。
COVID-19 影响分析
COVID-19大流行对市场产生了重大影响。这场大流行导致与该病毒相关的研究激增,包括患者样本的收集和储存。这增加了对低温保存服务和设施的需求。 COVID-19 疫苗的快速开发需要广泛的研究和测试。因此,越来越需要保存疫苗开发中使用的细胞株和材料。这场大流行凸显了为未来健康危机做好准备的重要性。各国政府和组织已经认识到需要装备精良的生物样本库和低温保存基础设施来有效应对未来的大流行,并鼓励在这些领域进行投资。这导致了更先进、更有效率的冷冻保存技术和设备的发展。
市场成长要素
增加卵子冷冻週期
人们对卵子冷冻的兴趣日益浓厚,对生育诊所、体外受精中心和生殖医学专家提供的冷冻保存服务的需求也随之增加。这些设施需要必要的基础设施,包括冷冻保存设备和专业知识,以提供卵子冷冻服务。对卵子冷冻的需求不断增长,刺激了冷冻保存技术和设备的技术进步。卵子冷冻库是卵子冷冻市场不可或缺的一部分,依靠专门的冷冻保存解决方案和设备来维持冷冻卵子的品质和活力。卵子冷冻週期的扩大有助于市场成长。
生物库的增加和个体化药物的需求
全球生物样本库的建立和扩散对细胞冷冻保存服务产生了巨大的需求。这些生物库依靠冷冻保存技术来保存和保存各种生物样本以供研究和临床使用。个人化医疗根据个别患者的遗传和特定需求提供量身定制的医疗护理,并且通常需要获得保存完好的生物样本。冷冻保存的样本可识别与多种疾病、药物反应和治疗结果相关的遗传标记和生物标记。生物样本库的增加和对个体化药物的需求正在扩大市场。
市场抑制因素
细胞冷冻保存替代疗法的可用性
替代方案的成本效益和可用性会影响其采用。如果替代方案更便宜或需要较少的专业设备,则在某些情况下可能会变得普及。采用替代冷冻保存方法可能取决于提高意识并教育研究人员和临床医生了解其好处和正确使用。检验冷冻保存替代方案的有效性和安全性是一个复杂的过程。替代方案可以与微流体和 3D 生物列印等其他技术和方法相结合,从而有可能改变低温保存市场的面貌。这些因素可能会降低未来几年的市场成长。
组件展望
根据成分,市场分为细胞冷冻介质、设备和消耗品。 2022年,消耗品部门以最大的销售占有率主导市场。细胞冻存消耗品对于超低温保存和储存细胞和组织至关重要,通常储存在液态氮或超低温冰箱中。这主要是由于最终用户越来越多地采用冷冻管、冷冻管和其他消耗品,因为它们具有污染少等优点。推动该行业成长的其他因素包括慢性病的增加、对生技药品的需求不断增长以及最终用户对冷冻保存的需求不断增长。
消耗品前景
依消耗品类型,市场进一步细分为低温瓶、低温管、冷却箱/容器等。 2022 年,低温瓶细分市场占据市场最高收益占有率。低温瓶由耐极冷的材料製成,确保保持样品的完整性。这有助于研究人员有效地定位和检索特定样本。低温瓶设计用于承受极端温度,并且可以在低温环境中安全使用。保护研究人员和实验室人员免受极低温度的影响。
细胞冷冻介质的展望
根据细胞冷冻介质类型,市场进一步细分为乙二醇、二甲基亚砜、甘油等。 2022年,乙二醇细分市场收益占有率最高。乙二醇透过进入细胞并抑製结晶的形成而充当冷冻保护剂。这对于细胞的存活很重要。冷冻介质中乙二醇的浓度可以根据特定方案和储存的细胞类型而变化。浓度经过精心选择,可提供有效的冷冻保护,同时最大限度地减少潜在毒性。
设备展望
按设备类型,市场进一步细分为冷冻机、培养箱和液态氮供应罐。 2022年,冰柜领域占据了市场上最大的收益占有率。冰箱透过提供在超低温下保存生物样本(包括细胞、组织和其他生物材料)所需的储存条件,在市场上发挥重要作用。冰箱是市场上必不可少的工具,可确保长期保存有价值的生物样本,以促进科学和医学进步。
最终用途展望
根据最终用途,市场分为生物製药和製药公司、研究机构、生物银行、体外受精诊所等。在2022年的市场中,生物样本库产业获得了很大的收益占有率。生物样本库对于储存和保存生物样本(包括组织和细胞)以用于研究和临床应用至关重要。根据国家医学图书馆的数据,到 2022 年,经济发达国家每百万人将拥有至少 11 个生物样本库。其目标是简化国际生物样本库的连接,并实现更大规模、更稳健的基因资料研究。该计划旨在透过增加更多的遗传祖先多样性来增加检测新的疾病相关遗传变异的可能性。
应用前景
依应用,市场分为干细胞、卵子/胚胎细胞、精子细胞、肝细胞等。到2022年,干细胞领域将占据市场最大的收益占有率。干细胞应用在很大程度上依赖细胞冷冻保存,它可以在不改变细胞或基因的情况下保存、储存和运输干细胞。根据世界卫生组织(WHF)2023年的记录,全球有超过5亿人受到心血管疾病(CVD)的影响,2021年将有约2050万人死亡,导致全球整体死亡人数最高。接近总数的三分之一。不断增长的老年人口,加上久坐的生活方式,将增加心血管疾病的负担,并刺激该行业的更大增长。
区域展望
从区域来看,我们对北美、欧洲、亚太地区和拉丁美洲/中东/非洲的市场进行了分析。 2022 年,亚太地区在市场中取得了显着的收益占有率。这是由于亚太地区,特别是中国和日本越来越多地采用细胞冷冻保存技术。该地区人口众多、慢性病多发、老年人口增加、不孕症比例快速上升,市场拓展空间广大。
The Global Cell Cryopreservation Market size is expected to reach $35.7 billion by 2030, rising at a market growth of 20.3% CAGR during the forecast period.
The surge in stem cell research has led to a growing demand for the banking of various types of stem cells, including embryonic stem cells, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells. Therefore, Stem Cells segment generated $3,228.6 million revenue in the market in 2022. As a result, the increasing focus on stem cell research has driven innovations in cryopreservation techniques specifically tailored to the needs of different stem cell types. These advancements have improved the viability and functionality of cryopreserved stem cells, expanding the capabilities of the market.
The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, In June, 2023, BioLife Solutions, Inc. unveiled IntelliRate i67C, a new, large-capacity controlled-rate freezer. This launch aimed to fulfill a crucial customer requirement for higher volume production of cell therapies. Moreover, In January, 2021, Lonza Group AG released cryopreserved Leukopaks, an expansion in renowned human primary cell offerings. The launched product would allow long-distance transportation of leukapheresis products without the concern of decreased cell viability encountered with fresh Leukopaks.
Based on the Analysis presented in the KBV Cardinal matrix; Thermo Fisher Scientific Inc and Danaher Corporation are the forerunners in the Market. In August, 2023, Thermo Fisher Scientific Inc. launched the TSV series of laboratory refrigerators and freezers, the Made in India. The launched product would offer controlled temperature technologies including ultra-low temperature freezers and cryopreservation storage tanks that guarantee temperature uniformity and stability, mitigating the risk of sample degradation. Companies such as Sartorius AG, Lonza Group AG and Merck KGAA are some of the key innovators in the Market.
COVID-19 Impact Analysis
The COVID-19 pandemic had a substantial impact on the market. The pandemic led to a surge in research related to the virus, including the collection and storage of patient samples. This increased demand for cryopreservation services and facilities. The rapid development of COVID-19 vaccines required extensive research and testing. This, in turn, led to an increased need for the preservation of cell lines and materials used in vaccine development. The pandemic highlighted the importance of preparedness for future health crises. Governments and organizations recognized the need for well-equipped biobanking and cryopreservation infrastructure to respond effectively to future outbreaks, which drove investment in these areas. This led to the development of more advanced and efficient cryopreservation techniques and equipment.
Market Growth Factors
Increasing number of egg-freezing cycles
The rising interest in egg freezing has increased the demand for cryopreservation services provided by fertility clinics, IVF centers, and reproductive medicine specialists. These facilities require the necessary infrastructure, including cryopreservation equipment and expertise, to offer egg-freezing services. The growing demand for egg freezing has spurred technological advancements in cryopreservation techniques and equipment. These banks are an integral part of the market, and they rely on specialized cryopreservation solutions and equipment to maintain the quality and viability of frozen eggs. The expansion of egg-freezing cycles has contributed to the growth of the market.
Growing number of biobanks and demand for personalized medicines
The establishment and growth of biobanks worldwide have created a significant demand for cell cryopreservation services. These biobanks rely on cryopreservation techniques to store and preserve diverse biological samples for research and clinical use. Personalized medicine, which tailors medical treatments to individual patients based on their genetics and specific needs, often requires access to well-preserved biological samples. Cryopreserved samples identify genetic markers and biomarkers associated with multiple diseases, drug responses, and treatment outcomes. The increasing number of biobanks and the demand for personalized medicines have expanded the market.
Market Restraining Factors
Availability of alternative therapies for cell cryopreservation
The cost-effectiveness and accessibility of alternative methods can influence their adoption. If alternative methods are more affordable or require less specialized equipment, they may gain popularity in specific contexts. Adopting alternative cryopreservation methods may depend on raising awareness and educating researchers and clinicians about their benefits and proper usage. Validating the effectiveness and safety of alternative methods for cryopreservation can be a complex process. Alternative methods may be integrated with other technologies or approaches, such as microfluidics or 3D bioprinting, which could change the landscape of the cryopreservation market. These factors will decline the market growth in the coming years.
Component Outlook
On the basis of component, the market is segmented into cell freezing media, equipment, and consumables. In 2022, the consumables segment dominated the market with the maximum revenue share. Cell cryopreservation consumable products are essential in preserving and storing cells and tissues at very low temperatures, typically in liquid nitrogen or ultra-low temperature freezers. This is primarily due to factors such as the increasing adoption of cryovials, cryotubes, and other consumables by end-users due to benefits such as lower contamination. Other aspects, including the rising majority of chronic diseases, growing demand for biologics, and rising demand for cryopreservation among end-users, will propel the segment's growth.
Consumables Outlook
Under consumables type, the market is further segmented into cryogenic vials, cryogenic tubes, cooler boxes/containers, and others. In 2022, the cryogenic vials segment held the highest revenue share in the market. Cryogenic vials are made of materials that are highly resistant to extreme cold, ensuring the preservation of sample integrity. This helps researchers efficiently locate and retrieve specific samples. Cryogenic vials are designed to withstand extreme temperatures and are safe for use in cryogenic environments. They protect researchers and laboratory personnel from exposure to ultra-low temperatures.
Cell Freezing Media Outlook
Under cell freezing media type, the market is further divided into ethylene glycol, dimethyl sulfoxide, glycerol, and others. In 2022, the ethylene glycol segment registered the highest revenue share in the market. Ethylene glycol acts as a cryoprotective agent by entering the cells and reducing ice crystal formation. This is important for cell survival. The concentration of ethylene glycol in freezing media can change depending on the specific protocol and the preserved cell type. The concentration is carefully chosen to provide effective cryoprotection while minimizing potential toxicity.
Equipment Outlook
Under equipment type, the market is further classified into freezers, incubators, and liquid nitrogen supply tanks. In 2022, the freezers segment generated the largest revenue share in the market. Freezers play a critical role in the market by providing the necessary storage conditions for preserving biological samples, including cells, tissues, and other biological materials, at ultra-low temperatures. They are vital tools in the market, ensuring the long-term preservation of valuable biological materials for scientific and medical advancements.
End-use Outlook
By end-use, the market is categorised into biopharmaceutical & pharmaceutical companies, research institutes, biobanks, IVF clinics, and others. The biobanks segment garnered a significant revenue share in the market in 2022. Biobanks are critical in the storage and preservation of biological samples, including tissues and cells, for research and clinical applications. According to the National Library of Medicine, economically developed countries had at least 11 biobanks per million people in 2022. Its goal is to simplify the connection of international biobanks, enabling larger and more robust genetic data investigations. This program intends to increase the possibility of detecting novel disease-associated genetic variations by adding more genetic ancestral variety.
Application Outlook
Based on application, the market is fragmented into stem cells, oocytes & embryotic cells, sperm cells, hepatocytes, and others. In 2022, the stem cells segment witnessed the largest revenue share in the market. Stem cell applications rely heavily on cell cryopreservation, which allows stem cells to be preserved, stored, and transported without cellular or genetic change. As per the World Health Federation- 2023 records, over half a billion people worldwide are affected by cardiovascular disorders (CVDs), with around 20.5 million deaths occurring in 2021, accounting for nearly one-third of all deaths globally. The growing senior population, combined with sedentary lifestyles, will raise the burden of cardiovascular disease, fueling the expansion of the segment growth.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific region recorded a remarkable revenue share in the market in 2022. Due to the rising adoption of cell cryopreservation technologies in the Asia Pacific region, especially throughout China and Japan. Because of the region's large population, the prevalence of chronic diseases, the rising number of older people, and the surge in the rate of infertility, there is enough scope for expanding the market in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., Sartorius AG, PromoCell GmbH, Lonza Group Ltd., HiMedia Laboratories Pvt. Ltd., Corning Incorporated, BioLife Solutions, Inc., Eppendorf SE and Danaher Corporation.
Recent Strategies Deployed in Cell Cryopreservation Market
Mergers & Acquisition
Jul-2023: Sartorius AG acquired Polyplus, a leading provider of innovative technologies for cell and gene therapies. Through this acquisition, both companies aimed to widen their focus in adjacent technologies like plasmid design, and protein and plasmid manufacturing, broadening their suites for gene therapies as well as gene-modified cell therapies.
Jul-2021: Sartorius AG took over Xell AG, an innovative partner for the biotech and pharmaceutical industry. This acquisition aimed to widen Sartorius's current media portfolio specifically by specialized media for manufacturing viral vectors and in the area of media analytics.
Mar-2020: Eppendorf AG took over Koki Holdings Co., Ltd., a Japan-based power/air tool manufacturer. This acquisition aimed to widen the Eppendorf centrifuge business and solidify its strong market position as one of the world's leading makers of high-end centrifuges for the pharma and life science industries including academic and commercial research.
Nov-2019: BioLife Solutions, Inc. acquired Custom Biogenic Systems, Inc., a privately held company with operations located near Detroit. This acquisition aimed to deepen engagement with BioLife Solutions cell and gene therapy customers and increase touchpoints in their manufacturing, storage, and distribution workflows.
Product Launches and Product Expansions
Aug-2023: Thermo Fisher Scientific Inc. launched the TSV series of laboratory refrigerators and freezers, the Made in India. The launched product would offer controlled temperature technologies including ultra-low temperature freezers and cryopreservation storage tanks that guarantee temperature uniformity and stability, mitigating the risk of sample degradation.
Jun-2023: BioLife Solutions, Inc. unveiled IntelliRate i67C, a new, large-capacity controlled-rate freezer. This launch aimed to fulfill a crucial customer requirement for higher volume production of cell therapies.
Oct-2022: Thermo Fisher Scientific Inc. introduced the new Gibco CTS DynaCellect Magnetic Separation System, to improve the cell therapy manufacturing process. The launched product would enable customers to commercialize therapies faster and potentially save more lives.
Apr-2021: BioLife Solutions, Inc. introduced a new suite of high-capacity controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company. The launched product would be a critical component in the customer's cold chain management of several allogeneic cell therapies in development.
Jan-2021: Lonza Group AG released cryopreserved Leukopaks, an expansion in renowned human primary cell offerings. The launched product would allow long-distance transportation of leukapheresis products without the concern of decreased cell viability encountered with fresh Leukopaks.
May-2020: Sartorius AG unveiled the Incucyte SX5 Live-Cell Analysis System, the latest in the company's portfolio of live-cell analysis products. The launched product would provide new capabilities, including novel optics, a new line of paired reagents, and purpose-built software to allow researchers to draw greater insight from each live cell experiment.
Partnerships, Collaborations & Agreements
Jul-2023: Sartorius AG came into collaboration with Qkine, a manufacturer of animal-free, highly bioactive, and innovative proteins. This collaboration aimed to allow rapid advancement in the science of advanced cell models.
Jun-2023: Sartorius AG collaborated with Stanford University, the leading research and teaching institution. This collaboration aimed to develop a Scalable Platform for Large-Scale Human iPSC Production.
Dec-2021: Sartorius AG partnered with HOF Sonderanlagenbau, a machinery company that manufactures freeze-drying, loading and unloading systems, freezing and thawing devices. This partnership aimed to empower Sartorius AG's leading position in the freeze-thaw market.
Dec-2021: Lonza Group AG collaborated with Agilent Technologies, a leader in life sciences analytics, diagnostics, and applied chemical markets. This collaboration aimed to change the way personalized cell therapies are manufactured and realized.
Jan-2021: Sartorius AG collaborated with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks. This collaboration aimed to scale of hMSC manufacturing for regenerative medicine by leveraging the best-in-class solutions of both companies to significantly decrease process development efforts.
Expansion
Jul-2023: Sartorius AG opened a cell culture media manufacturing facility in Yauco, Puerto Rico. The new facility would widen the company's cell culture media capacities, with a focus on customers in the Americas region.
Market Segments covered in the Report:
By Component
By End-use
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research